Covered recipient · General Payments record
RENAH T GIBSON
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$5,404.09
- Reported across 404 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $303.23 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $98.97 | 5 |
| Novo Nordisk AS | $64.44 | 4 |
| Amgen Inc. | $48.86 | 3 |
| Merck Sharp & Dohme Corporation | $34.45 | 2 |
| Acerta Pharma LLC | $22.00 | 1 |
| Axsome Therapeutics, Inc. | $19.60 | 1 |
| PFIZER INC. | $14.91 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $16.73 | 07/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103795537 | CMS |
| ABBVIE INC. | $20.44 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103795539 | CMS |
| ABBVIE INC. | $15.64 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103795541 | CMS |
| ABBVIE INC. | $28.91 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103795543 | CMS |
| ABBVIE INC. | $17.25 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103795545 | CMS |
| Amgen Inc. | $19.49 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117562122 | CMS |
| Amgen Inc. | $15.00 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117562124 | CMS |
| Amgen Inc. | $14.37 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115659963 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.00 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104639553 | CMS |
| Axsome Therapeutics, Inc. | $19.60 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148313956 | CMS |
| Merck Sharp & Dohme LLC | $15.66 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141700816 | CMS |
| Merck Sharp & Dohme LLC | $18.79 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141872107 | CMS |
| Novo Nordisk Inc | $13.78 | 02/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096604287 | CMS |
| Novo Nordisk Inc | $17.72 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096967814 | CMS |
| Novo Nordisk Inc | $15.39 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096615816 | CMS |
| Novo Nordisk Inc | $17.55 | 10/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096692311 | CMS |
| PFIZER INC. | $14.91 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132116020 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.